ReviewTranslational psychiatry2016
Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity.
Review in Translational psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Sex-specific differences in the relationship between prolactin and glucose metabolism in first-episode schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Grape-Derived Exosome-like Nanoparticles Ameliorate Prediabetes in Mice via Amino Acid Metabolic Reprogramming.International journal of molecular sciences · 2026Article
- Elevated prolactin and association with treatment resistance indicators in first-hospitalized schizophrenia spectrum disorders: a real-world cohort study.BMC psychiatry · 2025Article
- Genistein Reduces the Risk of Diabetes in Long-Term Hospitalized Schizophrenic Patients.Behavioral sciences (Basel, Switzerland) · 2025Article
- Effect of lurasidone plus sulpiride on treatment efficacy, psychiatric manifestations, and quality of life among patients with schizophrenia.World journal of psychiatry · 2025Article
- Sex-specific prolactin disturbance and divergent gonadal hormone correlates in first-episode schizophrenia.The international journal of neuropsychopharmacology · 2025Article
- Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).Molecular medicine reports · 2025Review
- Childhood trauma and relationship with the parents: associations with lipids, glucose, and prolactin levels during antipsychotic treatment in patients with first-episode psychosis.Frontiers in psychiatry · 2025Article
- Striatal dopamine gene network moderates the effect of early adversity on the risk for adult psychiatric and cardiometabolic comorbidity.Scientific reports · 2024Article
- Sini San ameliorates lipid metabolism in hyperprolactinemia rat with liver-depression.Current research in food science · 2024Article
- A systems biology approach for discovering the cellular and molecular aspects of psychogenic non-epileptic seizure.Frontiers in psychiatry · 2023Article
- Recent findings on subjective well-being and physical, psychiatric, and social comorbidities in individuals with schizophrenia: A literature review.Neuropsychopharmacology reports · 2022Review
- Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.International journal of molecular sciences · 2022Review
- Levels of Trace Elements in Erythrocytes as Endocrine Disruptors in Obese and Nonobese Women with Polycystic Ovary Syndrome.International journal of environmental research and public health · 2022Article
- Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus.The international journal of neuropsychopharmacology · 2021Review
- The Relationships Between Hyperprolactinemia, Metabolic Disturbance, and Sexual Dysfunction in Patients With Schizophrenia Under Olanzapine Treatment.Frontiers in pharmacology · 2021Article
- Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2019Review
- Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis.BMC psychiatry · 2018Article
- Prolactin selectively transported to cerebrospinal fluid from blood under hypoxic/ischemic conditions.PloS one · 2018Article
- Early Combination Therapy for Type 2 Diabetes Mellitus and Common Comorbid Mental Disorders.Focus (American Psychiatric Publishing) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia (SCZ) and type 2 diabetes (T2D) are clinically associated, and common knowledge attributes this association to side effects of antipsychotic treatment. However, even drug-naive patients with SCZ are at increased risk for T2D. Dopamine dysfunction has a central role in SCZ. It is well-known that dopamine constitutively inhibits prolactin (PRL) secretion via the dopamine receptor 2 (DR2D). If dopamine is increased or if dopamine receptors hyperfunction, PRL may be reduced. During the first SCZ episode, low PRL levels are associated with worse symptoms. PRL is essential in human and social bonding, as well as it is implicated in glucose homeostasis. Dopamine dysfunction, beyond contributing to SCZ symptoms, may lead to altered appetite and T2D. To our knowledge, there are no studies of the genetics of the SCZ-T2D comorbidity focusing jointly on the dopamine and PRL pathway in the attempt to capture molecular heterogeneity correlated to possible disease manifestation heterogeneity. In this dopamine-PRL pathway-focused-hypothesis-driven review on the association of SCZ with T2D, we report a specific revision of what it is known about PRL and dopamine in relation to what we theorize is one of the missing links between the two disorders. We suggest that new studies are necessary to establish the genetic role of PRL and dopamine pathway in SCZ-T2D comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.